An early-stage study funded by the National Institutes of Health found that diagnosis of autism based on video taken using an in-development smartphone app concurred with diagnosis using traditional, in-person methods 87% of the time.
Philadelphia's Graphene Frontiers is developing a hand-held, point-of-care diagnostic device that can detect heart attack biomarkers from a drop of blood within minutes, thanks to the use of the company's namesake material.
Shervin Pishevar, one of the earlier backers of new-age taxi service Uber, is throwing his support behind San Diego startup Cue, which is developing a home-enabled diagnostic for testing for testosterone, fertility, inflammation, vitamin D and influenza.
The head of Google's life sciences team drummed up already-high interest in the company's developmental stage wearable diagnostic. The device will use magnets to "call" diagnostic nanoparticles so small that millions fit within a grain of sand, said life science team leader and Google X lab member Andrew Conrad at the WSJD Live conference
The DNA Medicine Institute, developer of a diagnostic device that can perform hundreds of clinical lab tests with a single drop of blood, won the Nokia Sensing Xchallenge for promising medical sensing technologies.
Google has dedicated more than 100 employees from multiple disciplines to making its vision of nanotechnology-enabled detection of cancer and other diseases a reality. Any tangible product resulting from this ambitious effort is at least 5 to 7 years away.
Established point-of-care diagnostics company Welch Allyn has partnered with wearables startup Gentag to develop medical devices that use wireless sensors.
Alere continued down the path of deleveraging and refocusing on its core competency in diagnostics with the sale of its Alere Health unit to Optum, a part of the insurance company UnitedHealth Group for $600 million.
The U.S. Food and Drug Administration has given a temporary thumbs up to Ebola test FilmArray BioThreat-E from BioFire Defense, a bioMérieux company. The test offers results in one hour rather than the one to two days required by existing methods.
Startup Gamma Medica is aiming to improve the odds and lower the cost of effective imaging of dense breast tissue with its molecular breast imaging tool. Now, it's gained a cash infusion of $11.5 million to aid in its commercialization efforts.